MESOTHELIOMA MEDICAL JOURNAL ARTICLES

Abstracts of recent articles about mesothelioma in medical journals. Many of these are available through PubMed, a search engine of the National Library of Medicine. Overview of mesothelioma in PDF format. See our page on how to read medical abstracts.

1. Detection of integrin-linked kinase in the serum of patients with malignant pleural mesothelioma.
2. Malignant Pleural Mesothelioma After Household Exposure to Asbestos.
3. Synergistic effect of gefitinib and rofecoxib in mesothelioma cells.
4. Successful salvage chemotherapy with gemcitabine and vinorelbine in a malignant pleural mesothelioma patient previously treated with pemetrexed.
5. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.
6. The sensitivity of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma.
7. Lung Cancer Mutation Consortium news
8. Onconase mediated NFKβ downregulation in malignant pleural mesothelioma
9. Antiproliferative effect of Aurora kinase targeting in mesothelioma.
10. Multi-institutional experience of diffuse intra-abdominal multicystic peritoneal mesothelioma.
11. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.
12. Re-evaluation of histological diagnoses of malignant mesothelioma by immunohistochemistry
13. Induction of tubulin polymerization and apoptosis in malignant mesothelioma cells by a new compound JBIR-23.
14. Successful salvage chemotherapy with gemcitabine and vinorelbine in a malignant pleural mesothelioma patient previously treated with pemetrexed.
15. Soluble Mesothelin-Related Peptide and Osteopontin As Markers of Response in Malignant Mesothelioma
16. Malignant mesothelioma following treatment for Hodgkin’s disease
17. Treatment with interleukin-2 in malignant pleural mesothelioma: immunological and angiogenetic assessment and prognostic impact
18. Occupational exposure to asbestos and mortality among asbestos removal workers: a Poisson regression analysis.
19. A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy
20. A theoretical quantitative model for evolution of cancer chemotherapy resistance
21. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-Institutional Experience
22. Malignant Pleural Mesothelioma After Household Exposure to Asbestos
23. Late cutaneous metastases to the face from malignant pleural mesothelioma: A case report and review of the literature
24. Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines.
25. A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy
26. Osteopontin-mediated enhanced hyaluronan binding induces multidrug resistance in mesothelioma cells.
27. Positron emission tomography predicts survival in malignant pleural mesothelioma.
28. Synergistic effect of gefitinib and rofecoxib in mesothelioma cells
29. Three Emerging New Drugs for NSCLC: Pemetrexed, Bortezomib, and Cetuximab
30. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group.
31. Diagnosis of epithelial mesothelioma using tree-based regression analysis and a minimal panel of antibodies.
32. Problems in mesothelioma diagnosis.
33. Therapeutic strategies for resectable malignant pleural mesothelioma
34. Comparison of CT and integrated PET-CT based radiation therapy planning in patients with malignant pleural mesothelioma.
35. Surgical biology for the clinician: peritoneal mesothelioma: current understanding and management.
36. Sarcomatoid mesothelioma: a clinical-pathologic correlation of 326 cases
37. Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma.
38. Second-line treatment for malignant pleural mesothelioma
39. Sarcomatoid mesothelioma: a clinical-pathologic correlation of 326 cases.
40. Genome-Wide PComparison of CT and integrated PET-CT based radiation therapy planning in patients with malignant pleural mesothelioma.rofile of Pleural Mesothelioma versus Parietal and Visceral Pleura: The Emerging Gene Portrait of the Mesothelioma Phenotype
41. Fatal hemopericardial tamponade due to primary pericardial mesothelioma: a case report
42. Cisplatin-induced expression of Gb3 enables verotoxin-1 treatment of cisplatin resistance in malignant pleural mesothelioma cells
43. Screening for malignant pleural mesothelioma and lung cancer in individuals with a history of asbestos exposure.
44. Diagnosis and staging of pleural mesothelioma – English language abstract of a Japanese paper.
45. Survival and relapse pattern after trimodality therapy for malignant pleural mesothelioma.
46. Malignant mesothelioma – Review from the Orphanet Journal of Rare Diseases
47. Malignant pleural mesothelioma: an update on biomarkers and treatment.
48. Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program.
49. Cisplatin-induced expression of Gb3 enables verotoxin-1 treatment of cisplatin resistance in malignant pleural mesothelioma cells
50. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma
51. Cytoreductive surgery and intraperitoneal chemotherapy for peritoneal mesothelioma
52. Pathways affected by asbestos exposure in normal and tumour tissue of lung cancer patients
53. Malignant pleural mesothelioma: computed tomography and correlation with histology.
54. “Mucin-positive” epithelial mesothelioma of the peritoneum: an unusual diagnostic pitfall.
55. Long-term mortality from pleural and peritoneal cancer after exposure to asbestos: Possible role of asbestos clearance.
56. Malignant mesothelioma following treatment for Hodgkin’s disease
57. Susceptibility and resistance in the genesis of asbestos-related mesothelioma
58. Phase II Study of Erlotinib in Patients With Malignant Pleural Mesothelioma: A Southwest Oncology Group Study
59. Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent.
60. Asbestos-related cancer risk in the presence of asbestosis or pleural plaques
61. Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials.
62. Multidisciplinary treatment of malignant pleural mesothelioma.
63. An epidemiological study of the role of chrysotile asbestos fibre dimensions in determining respiratory disease risk in exposed workers.
64. Symptomatic and quality of life changes after extrapleural pneumonectomy for malignant pleural mesothelioma.
65. Cellular and molecular mechanisms of asbestos carcinogenicity: implications for biopersistence.
66. Long-term mortality from pleural and peritoneal cancer after exposure to asbestos: Possible role of asbestos clearance.
67. Malignant pleural mesothelioma: Computed tomography and correlation with histology
68. A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma